This Listing is for the large bottle of Capsules
Results are faster and more pronounced when using both together.
1 bottle of 90 soft gel caps 3 caps contain 1.05g esterified fatty acid complex.
NORMAL RETAIL COST IS $35.00
Esterified Fatty Acid Complex (EFAC) is a major medical advancement
that was awarded a U.S. patent in 2009 (7,612,111) for its unprecedented
anti-inflammatory properties. Both EFAC capsules and pain cream are
clinically proven with extensive research and no reported side effects.
Put simply…EFAC WORKS!
Who Can Benefit From EFAC?
EFAC has been clinically shown to improve range of motion
and restore joint health with no side effects. That's because EFAC
lubricates cell membranes throughout the body. This includes the
enhancement of fluids that cushion your bones and joints so that you can
move with ease. The health of your cell membranes affects numerous
conditions, even the “process of aging” is greatly impacted by cell
membrane lubrication. We therefore feel that people wanting to improve
the health of their joints or anyone 40 to 45 years of age and up can
potentially benefit from EFAC’s lubricating affect on cell membranes.
The BEST science has to offer
-- EFAC Pain Cream and Capsules Complement your care with EFAC!
EFAC - Feel the Difference
• Pain Relief in Minutes
SAFE and EFFECTIVE
Are you using clinically proven products?
FEEL the Difference Science Can Make
Evidenced based approaches
provide us with the tools needed to help patients and at the same time
protect and advance natural therapeutics. We are committed to the
sharing of credible information. Informed patients make informed
decisions. We will do all we can to help educate your patients, and as a
result you can expect more fully committed patients.
There is scientific support for natural approaches, but at the same
time there are a lot of half truths and at times totally misleading
statements made in order to sell products. We will let the science speak
EFAC Proven Safe and Effective
EFAC has been studied with seventeen (17) animal and clinical
studies, with six (6) studies presented at scientific meetings and four
(4) published in pre-eminent scientific journals – two of which have
been published in the prestigious medical journal, The Journal of
Additionally two studies were published in the Journal of Periodontology in 2009. Not only were the
esterified oils effective against the animals periodontal infections,
which in itself is a major breakthrough, as there are few if any
effective options, but in the 2009 study the researchers revealed that
the esterified oils led to the restoration of both connective and
US Patent Awarded
As a testament to the importance of all this research, a US
patent (#7,612,111) was awarded in 2009 for the unprecedented
anti-inflammatory properties of esterified oils.
Udani Arthritis Abstract EFAC
This is recently completed research using EFAC as an oral supplement
for osteoarthritis (OA) of the knee. This was a double blind, placebo
controlled trial with 93 patients.
The trial participant’s pain levels were assessed. However a
perhaps more interesting aspect of this study was that an objective
functional parameter was also measured. Patients were tested prior to
starting medication and then after 2, 4 and 8 weeks to see how far they
could walk in 6 minutes. Presumably the pain and stiffness of knee OA
would cause one to walk slower and if pain relief occurred, then one
could then speed up and walk farther in the given time. Patients
receiving EFAC had less pain and were able to walk 233 feet farther
after just 2 weeks. And they continued to improve over time with less
pain and an increased distance walked. After 8 weeks they walked on
average 537 feet farther than they could at the beginning of the
clinical trial. A truly amazing result! Just as impressive was the
difference between the two groups, as those receiving the placebo did
not improve, which implies that the results were due to EFAC and not
something else such as improved fitness levels.
first prize . . .
out of the 90 papers presented at the
Scripps Medical Conference
San Diego CA, in 2007.
JOURNAL of RHEUMATOLOGY-2002
EFAC Improves Knee Function in OA Patients
This placebo controlled clinical trial of EFAC as an oral
supplement was the first to investigate whether EFAC could be used to
treat osteoarthritis (OA) of the knee. The overall function of the
knees, as well the range of motion improved in the patients receiving
EFAC. This very successful study paved the way for the other studies.
JOURNAL OF RHEUMATOGY-2004
Effect of a EFAC Topical Cream on Functional
This double blind, placebo controlled clinical trial
investigated whether EFAC topical cream could improve the functional
mobility of patients with OA of the knees, since these patients
typically have impaired physical performance, presumably at least in
part due to pain. Patients were tested at baseline and then 30 minutes
later to determine the short-term effects and also 30 days later after
applying the cream twice daily for long-term effects.
The EFAC cream was found to increase the range of motion of
the knees, improve the ability of patients to ascend and descend stairs,
made it easier to get up from a sitting position and improved the
balance of patients stepping down.
Most interesting was the result that after only 30 minutes
of the first application of EFAC cream there were real improvements.
Further improvements were recorded after a month, demonstrating that the
cream provides not only short-term benefit, but also cumulative
long-term benefit with regular daily use.
Journal of Strength & Conditioning Research, 2005
Effect of EFAC on Static Postural Stability and Plantar
Distribution in Patients with Knee Osteoarthritis
Data indicated that 30 days of treatment with a topical cream
consisting of EFAC improves static postural stability in patients with
knee OA presumably due to pain relief during quiet standing.
Journal of Strength & Conditioning Research,
EFAC Topical Cream with Menthol Reduces Pain and Improves
Functional Performance in Individuals with Arthritis
Our EFAC cream is comprised of EFAC and a minimal amount of
menthol (1.25%). This clinical trial was designed to test whether
menthol affected the efficacy, since previous tests were
conducted without menthol. Patients with either OA of the
knee, elbow or wrist were tested. One week of treatment of the cream
containing menthol was found to be similarly effective for reducing pain
and improving functional performance as prior tests that used EFAC
cream without menthol.
EFAC vs Glucosamine Cochrane Collaborative
The Cochrane Collaboration is an international,
not-for-profit, independent organization that produces and disseminates
systematic reviews of health care interventions. Cochrane is one of the
most, if not the most respected organization of its type in the world.
According to their 2010, issue # 4 review of glucosamine, which included
25 studies with 4963 patients, only one brand of glucosamine was found
more effective than placebo. The brand is called Rotta and is the
original glucosamine from Italy. The vast majority of the glucosamine
used in America is not Rotta brand. It is quite amazing that so
many people, including physicians just assume that glucosamine is
effective. This is understandable when we consider how much joint health
advertising that takes place. The sad reality is that in well
controlled clinical trials that the placebo pills produced
just as good effects as glucosamine.
GAIT Glucosamine Arthritis Intervention Trial
The clinical trial that highlights the confusion surrounding
glucosamine better than any other is the GAIT
Glucosamine Arthritis Intervention Trial.
GAIT is the largest and most rigorous investigation of glucosamine that
has ever taken place in America. The GAIT trial took place at 16
universities across America, was conducted by the NIH or the National
Institute for Health and included 1583 patients.
In Gait, participants were randomly assigned to one
of 10 treatment groups:
2 groups received glucosamine only,
2 groups received chondroitin only,
2 groups received the combination of glucosamine and
2 groups received Celebrex the drug and 2 groups received a
5 of the 6 glucosamine and/or chondroitin
groups failed to show benefit over the placebo for pain relief after 6
Only 1 of the 6, which was a group receiving
both glucosamine and chondroitin appeared to benefit. This group was
small with only 72 participants and as a result just a few patients
either way could make the difference between a benefit or no benefit
relative to the placebo groups.
Even the GAIT researchers cautioned not to draw any
conclusions from this 6th group because of its small size and also very
importantly because the results were inconsistent with the results from
the other 5 groups.
Joint Spacing and Cartilage Loss
GAIT participants were given the opportunity to continue for
another 18 months in order to see if there were any benefits to the
cartilage after 2 years. If glucosamine and/or chondroitin was
beneficial to the cartilage, then the researchers would see a reduction
in cartilage loss. When the cartilage and joint spacing was measured the
result was that there was no statistically significant difference
between the glucosamine/chondroitin groups and placebo. Ironically the
participants receiving both glucosamine and chondroitin had slightly
more cartilage loss than placebo. It was a minor difference and not
statistically significant, but certainly not a benefit!
Now for the confusing part. Companies selling glucosamine
often refer to GAIT as proof that glucosamine works, despite the
researcher’s conclusions that overall there were no benefits over
placebo. There were even TV ads referring to GAIT. The ads sounded very
credible, as they said that glucosamine was clinically proven in the
GAIT trial, which was conducted by the NIH. For most people a trial
conducted by the NIH would certainly sound credible. Glucosamine was
proven in GAIT, but if anything, proven ineffective! Advertisers have
frequently referred to GAIT and the 72 patient’s that seem to benefit,
but they fail to mention the other 95% of trial participants or the fact
that this 72 patient group went on to experience more cartilage loss
than placebo. Of course everyone is confused!
The simple truth is that glucosamine does not
compare to EFAC.
Your patients deserve the best science has to offer. If you
are dispensing a joint health product, then use EFAC- it’s far more
effective and much faster acting than glucosamine.
EFAC - Feel
the Difference Science Can Make
EFAC—TRUST the SCIENCE!
Packaging may vary slightly from the picture due to manufacture chioce.